P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Preliminary studies have supported the background efficacy of local standard anti-malarial
medications in the treatment of uncomplicated knowlesi malaria, however this has not been
tested systematically and there are no current WHO treatment guidelines for this infection.
There are both health cost benefits to a more rapidly acting agent, and due to difficulties
with microscopic identification there may be more effective treatment for all malaria species
if an aligned treatment guideline could be supported. In addition, no therapeutic efficacy
monitoring of current first line anti-malarials used for the treatment of P. vivax malaria
have been conducted in Malaysia.
The investigators aim to test whether the fixed combination of artesunate-mefloquine is
superior to chloroquine in order to define the optimal treatment for both uncomplicated P.
knowlesi and P. vivax infection in both adults and children in this region.